On the role of diagnosis of prostate diseases at the outpatient appointment of a therapist

Malignant diseases remain an important problem in medicine, while its solution depends on the effectiveness of detecting the early stages of cancer at the outpatient stage, including the therapeutic link in the provision of medical care. Currently existing approaches to the promotion of the foundations of a healthy lifestyle are mainly aimed only at the prevention of behavioral risk factors: tobacco smoking, unhealthy diet, insufficient physical activity and harmful use of alcohol. At the same time, according to experts, even exposure only to them will prevent at least 40% of cases of the development of malignant ovariances. A 3-tier system of medical care has been organized in Russia. It is the first level of primary health care that should ensure the prophylactic focus of health care: competent clinical examination is able to provide a significant, up to 30%, contribution to reducing the overall mortality of the population, including mortality from malignant neoplasms. The first stage in the diagnosis of oncological disease are therapists, to whom patients come with general complaints (fatigue, low-grade fever, joint pain, dysuria, etc.). The most urgent task in the work of a general practitioner is the timely detection of a tumor disease and referral of a patient for treatment to an oncologist. The article considers the possibilities of screening measures with the participation of therapists, general practitioners, and offers specially developed algorithms for the diagnosis of benign and malignant neoplasms of the prostate gland. The formation of oncological alertness skills in a primary outpatient care physician is necessary for early detection and reduction of the incidence of advanced stages of tumors and earlier initiation of specialized treatment. Identification of symptoms suspicious of malignant neoplasms using algorithmic approaches and subsequent consultation with the patient by a specialist urologist or oncologist should improve treatment outcomes.

1. Malignant neoplasms in Russia in 2019 (morbidity and mortality) / Ed. Kaprin A. D., Starinsky V. V., Petrova G. V. M.: MNIOI P. A. Herzen branch of the National Medical Research Center of Radiology, 2020. 252 p. (In Russ.)

2. Barchuk A., Bespalov A., Huhtala H., et al. Productivity losses associated with premature mortality due to cancer in Russia: A populationwide study covering 2001-2030 // Scand J Public Health. 2019; 47 (5): 482-491. DOI: 10.1177/1403494819845565.

3. Alexandrova L. M., Starinskiy V. V., Kaprin A. D. et al. Prevention of oncological diseases as the basis for interaction of the oncological service with primary health care // Research and practice in medicine. 2017; 4 (1): 74-80. (In Russ.) DOI: 10.17709/2409-2231-2017-41-10.

4. Sycheva A. S., Kebina A. L., Nosova A. V., Vertkin A. L. The principles of oncological alertness at the outpatient therapeutic stage // Lechaschi Vrach. 2021; 8: 48-52. (In Russ.)

5. Seregina I. F., Drapkina O. M., Kolokolov A. V., et al. Quality issues of preventive and prophylactic medical examinations of adult population and feasible solutions // Roszdravnadzor Bulletin. 2020; 5-1: 51-59. (In Russ.)

6. Kiselev I. L., Khvostova V. V., Dolgin V. I. et al. Analysis of malignancies among health care workers in primary care. Materials of the First International Forum of Oncology and Radiology. Moscow, September 23-27, 2019 p. 143. (In Russ.)

7. Adenoma of the prostate. Urology. National leadership. Ed. N. A. Lopatkin. M.: GeotarMedia, 2013. 1024 p. (In Russ.)

8. Pushkar D. Yu., Rasner P. I. Lower urinary tract symptoms and benign prostatic hyperplasia // Urology. 2018; S1: 30-45. (In Russ.)

9. Vertkin A. L. Gender & Symptoms Med // Alphabet. 2021; 7: 8-10. (In Russ.)

10. Reva S. A., Kudinova N. I., Lapin S. V., Petrov S. B. Genetic research as a method for assessing susceptibility to prostate cancer // Urology Herald. 2020; 8 (3): 103-110. (In Russ.) DOI:10.21886/2308-6424-2020-8-3-103-110.

11. Vertkin A. L., Pushkar D. Yu. Age-related androgen deficiency and erectile dysfunction. M.: GEOTAR-Media, 2009. 176 p. (In Russ.)

12. Ponkratov S. V., Oleksjuk A. V., Oleksjuk I. B., Kozlov K. L. Age as one of the important criteria of prostate cancer diagnostic // Advances in Gerontology. 2021; 3 (34): 404-408. (In Russ.)

13. Alyaev Yu. G., Bezrukov Ye. A., Shestiperov P. A. Molecular pathology of prostate cancer: diagnostic and prognostic value of major markers // Oncourology. 2006; 2: 45-50. (In Russ.)

14. Vertkin A. L., Gritsanchuk A. M. Pulmonary embolism: an epidemic that everyone is silent about // Arkhiv vnutrenney meditsiny. 2014; 1: 33-9. (In Russ.)

15. Sycheva A. S., Vertkin A. L., Kebina A. L. Oncological alertness in patients at outpatient therapeutic stage // Med. Alphabet. 2021; 7: 41-45. (In Russ.)

16. Kaprin A. D., Starinskiy V. V., Petrova G. V. The state of cancer care for the population of Russia in 2012. Moscow: MNIOI P. A. Herzen, 2013. 231 p. (In Russ.)

17. Kostin A. A., Starinskiy V. V., Samsonov Yu. V., Asratov A. T. Analysis of statistical data on malignant neoplasms // Research and practice in medicine. 2016; 1 (3): 66-78. (In Russ.)

18. Pushkar D. Yu., Govorov A. V., Vasilyev A. O., ct al. Moscow program of early detection and treatment of prostate cancer // Problems of social hygiene, public health and history of medicine. 2019; 27: 677-686. (In Russ.)